Arecor Therapeutics (LSE:AREC) 3-Year Revenue Growth Rate : 34.70% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics 3-Year Revenue Growth Rate?

Arecor Therapeutics's Revenue per Share for the six months ended in Dec. 2023 was £0.10.

During the past 12 months, Arecor Therapeutics's average Revenue per Share Growth Rate was 79.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 34.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 28.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 7 years, the highest 3-Year average Revenue per Share Growth Rate of Arecor Therapeutics was 45.40% per year. The lowest was 0.70% per year. And the median was 34.70% per year.

Competitive Comparison of Arecor Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Arecor Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arecor Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's 3-Year Revenue Growth Rate falls into.

Arecor Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Arecor Therapeutics (LSE:AREC) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Arecor Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.